oru.sePublications
Change search
Link to record
Permanent link

Direct link
BETA
Alternative names
Publications (10 of 223) Show all publications
Steyerberg, E. W., Wiegers, E., Sewalt, C., Buki, A., Citerio, G., De Keyser, V., . . . Menon, D. K. (2019). Case-mix, care pathways, and outcomes in patients with traumatic brain injury in CENTER-TBI: a European prospective, multicentre, longitudinal, cohort study.. Lancet Neurology, 18(10), 923-934, Article ID S1474-4422(19)30232-7.
Open this publication in new window or tab >>Case-mix, care pathways, and outcomes in patients with traumatic brain injury in CENTER-TBI: a European prospective, multicentre, longitudinal, cohort study.
Show others...
2019 (English)In: Lancet Neurology, ISSN 1474-4422, E-ISSN 1474-4465, Vol. 18, no 10, p. 923-934, article id S1474-4422(19)30232-7Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: The burden of traumatic brain injury (TBI) poses a large public health and societal problem, but the characteristics of patients and their care pathways in Europe are poorly understood. We aimed to characterise patient case-mix, care pathways, and outcomes of TBI.

METHODS: CENTER-TBI is a Europe-based, observational cohort study, consisting of a core study and a registry. Inclusion criteria for the core study were a clinical diagnosis of TBI, presentation fewer than 24 h after injury, and an indication for CT. Patients were differentiated by care pathway and assigned to the emergency room (ER) stratum (patients who were discharged from an emergency room), admission stratum (patients who were admitted to a hospital ward), or intensive care unit (ICU) stratum (patients who were admitted to the ICU). Neuroimages and biospecimens were stored in repositories and outcome was assessed at 6 months after injury. We used the IMPACT core model for estimating the expected mortality and proportion with unfavourable Glasgow Outcome Scale Extended (GOSE) outcomes in patients with moderate or severe TBI (Glasgow Coma Scale [GCS] score ≤12). The core study was registered with ClinicalTrials.gov, number NCT02210221, and with Resource Identification Portal (RRID: SCR_015582).

FINDINGS: Data from 4509 patients from 18 countries, collected between Dec 9, 2014, and Dec 17, 2017, were analysed in the core study and from 22 782 patients in the registry. In the core study, 848 (19%) patients were in the ER stratum, 1523 (34%) in the admission stratum, and 2138 (47%) in the ICU stratum. In the ICU stratum, 720 (36%) patients had mild TBI (GCS score 13-15). Compared with the core cohort, the registry had a higher proportion of patients in the ER (9839 [43%]) and admission (8571 [38%]) strata, with more than 95% of patients classified as having mild TBI. Patients in the core study were older than those in previous studies (median age 50 years [IQR 30-66], 1254 [28%] aged >65 years), 462 (11%) had serious comorbidities, 772 (18%) were taking anticoagulant or antiplatelet medication, and alcohol was contributory in 1054 (25%) TBIs. MRI and blood biomarker measurement enhanced characterisation of injury severity and type. Substantial inter-country differences existed in care pathways and practice. Incomplete recovery at 6 months (GOSE <8) was found in 207 (30%) patients in the ER stratum, 665 (53%) in the admission stratum, and 1547 (84%) in the ICU stratum. Among patients with moderate-to-severe TBI in the ICU stratum, 623 (55%) patients had unfavourable outcome at 6 months (GOSE <5), similar to the proportion predicted by the IMPACT prognostic model (observed to expected ratio 1·06 [95% CI 0·97-1·14]), but mortality was lower than expected (0·70 [0·62-0·76]).

INTERPRETATION: Patients with TBI who presented to European centres in the core study were older than were those in previous observational studies and often had comorbidities. Overall, most patients presented with mild TBI. The incomplete recovery of many patients should motivate precision medicine research and the identification of best practices to improve these outcomes.

FUNDING: European Union 7th Framework Programme, the Hannelore Kohl Stiftung, OneMind, and Integra LifeSciences Corporation.

National Category
Neurology
Identifiers
urn:nbn:se:oru:diva-77193 (URN)10.1016/S1474-4422(19)30232-7 (DOI)31526754 (PubMedID)
Available from: 2019-10-11 Created: 2019-10-11 Last updated: 2019-10-11
Vande Vyvere, T., Wilms, G., Claes, L., Martin Leon, F., Nieboer, D., Verheyden, J., . . . European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI), I. a. (2019). Central versus Local Radiological Reading of Acute Computed Tomography Characteristics in Multi-Center Traumatic Brain Injury Research.. Journal of Neurotrauma, 36(7), 1080-1092
Open this publication in new window or tab >>Central versus Local Radiological Reading of Acute Computed Tomography Characteristics in Multi-Center Traumatic Brain Injury Research.
Show others...
2019 (English)In: Journal of Neurotrauma, ISSN 0897-7151, E-ISSN 1557-9042, Vol. 36, no 7, p. 1080-1092Article in journal (Refereed) Published
Abstract [en]

Observer variability in local radiological reading is a major concern in large-scale multi-center traumatic brain injury (TBI) studies. A central review process has been advocated to minimize this variability. The aim of this study is to compare central with local reading of TBI imaging datasets and to investigate the added value of central review. A total of 2050 admission computed tomography (CT) scans from subjects enrolled in the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study were analyzed for seven main CT characteristics. Kappa statistics were used to calculate agreement between central and local evaluations and a center-specific analysis was performed. The McNemar test was used to detect whether discordances were significant. Central interobserver and intra-observer agreement was calculated in a subset of patients. Good agreement was found between central and local assessment for the presence or absence of structural pathology (CT+, CT-, κ = 0.73) and most CT characteristics (κ = 0.62 to 0.71), except for traumatic axonal injury lesions (κ = 0.37). Despite good kappa values, discordances were significant in four of seven CT characteristics (i.e., midline shift, contusion, traumatic subarachnoid hemorrhage, and cisternal compression; p = 0.0005). Central reviewers showed substantial to excellent interobserver and intra-observer agreement (κ = 0.73 to κ = 0.96), contrasted by considerable variability in local radiological reading. Compared with local evaluation, a central review process offers a more consistent radiological reading of acute CT characteristics in TBI. It generates reliable, reproducible data and should be recommended for use in multi-center TBI studies.

Place, publisher, year, edition, pages
Mary Ann Liebert, 2019
Keywords
Agreement, central radiology review, traumatic brain injury
National Category
Clinical Medicine Neurology
Identifiers
urn:nbn:se:oru:diva-76158 (URN)10.1089/neu.2018.6061 (DOI)000450729800001 ()30259789 (PubMedID)2-s2.0-85063277328 (Scopus ID)
Available from: 2019-09-06 Created: 2019-09-06 Last updated: 2019-09-19Bibliographically approved
Lamichhane, S., Kemppainen, E., Trošt, K., Siljander, H., Hyöty, H., Ilonen, J., . . . Oresic, M. (2019). Circulating metabolites in progression to islet autoimmunity and type 1 diabetes. Diabetologia
Open this publication in new window or tab >>Circulating metabolites in progression to islet autoimmunity and type 1 diabetes
Show others...
2019 (English)In: Diabetologia, ISSN 0012-186X, E-ISSN 1432-0428Article in journal (Refereed) Epub ahead of print
Abstract [en]

AIMS/HYPOTHESIS: Metabolic dysregulation may precede the onset of type 1 diabetes. However, these metabolic disturbances and their specific role in disease initiation remain poorly understood. In this study, we examined whether children who progress to type 1 diabetes have a circulatory polar metabolite profile distinct from that of children who later progress to islet autoimmunity but not type 1 diabetes and a matched control group.

METHODS: We analysed polar metabolites from 415 longitudinal plasma samples in a prospective cohort of children in three study groups: those who progressed to type 1 diabetes; those who seroconverted to one islet autoantibody but not to type 1 diabetes; and an antibody-negative control group. Metabolites were measured using two-dimensional GC high-speed time of flight MS.

RESULTS: In early infancy, progression to type 1 diabetes was associated with downregulated amino acids, sugar derivatives and fatty acids, including catabolites of microbial origin, compared with the control group. Methionine remained persistently upregulated in those progressing to type 1 diabetes compared with the control group and those who seroconverted to one islet autoantibody. The appearance of islet autoantibodies was associated with decreased glutamic and aspartic acids.

CONCLUSIONS/INTERPRETATION: Our findings suggest that children who progress to type 1 diabetes have a unique metabolic profile, which is, however, altered with the appearance of islet autoantibodies. Our findings may assist with early prediction of the disease.

Place, publisher, year, edition, pages
Springer, 2019
Keywords
Beta cell autoimmunity, Metabolomics, Type 1 diabetes
National Category
Other Basic Medicine
Identifiers
urn:nbn:se:oru:diva-75892 (URN)10.1007/s00125-019-04980-0 (DOI)31444528 (PubMedID)
Available from: 2019-08-26 Created: 2019-08-26 Last updated: 2019-08-30Bibliographically approved
Lamichhane, S., Ahonen, L., Dyrlund, T. S., Dickens, A. M., Siljander, H., Hyöty, H., . . . Oresic, M. (2019). Cord-Blood Lipidome in Progression to Islet Autoimmunity and Type 1 Diabetes. Biomolecules, 9(1), Article ID E33.
Open this publication in new window or tab >>Cord-Blood Lipidome in Progression to Islet Autoimmunity and Type 1 Diabetes
Show others...
2019 (English)In: Biomolecules, E-ISSN 2218-273X, Vol. 9, no 1, article id E33Article in journal (Refereed) Published
Abstract [en]

Previous studies suggest that children who progress to type 1 diabetes (T1D) later in life already have an altered serum lipid molecular profile at birth. Here, we compared cord blood lipidome across the three study groups: children who progressed to T1D (PT1D; n = 30), children who developed at least one islet autoantibody but did not progress to T1D during the follow-up (P1Ab; n = 33), and their age-matched controls (CTR; n = 38). We found that phospholipids, specifically sphingomyelins, were lower in T1D progressors when compared to P1Ab and the CTR. Cholesterol esters remained higher in PT1D when compared to other groups. A signature comprising five lipids was predictive of the risk of progression to T1D, with an area under the receiver operating characteristic curve (AUROC) of 0.83. Our findings provide further evidence that the lipidomic profiles of newborn infants who progress to T1D later in life are different from lipidomic profiles in P1Ab and CTR.

Place, publisher, year, edition, pages
MDPI, 2019
Keywords
Autoimmunity, cord blood, lipidomics, metabolomics, type 1 diabetes
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:oru:diva-71853 (URN)10.3390/biom9010033 (DOI)000458051700033 ()30669674 (PubMedID)2-s2.0-85060365305 (Scopus ID)
Note

Funding Agencies:

JDRF  4-1998-274  4-1999-731 4-2001-435 

Special research funds for Oulu, Tampere and Turku University Hospitals in Finland  

Juvenile Diabetes Research Foundation  2-SRA-2014-159-Q-R 

Academy of Finland (Centre of Excellence in Molecular Systems Immunology and Physiology Research-SyMMyS)  250114 

Available from: 2019-02-12 Created: 2019-02-12 Last updated: 2019-06-19Bibliographically approved
van Essen, T. A., den Boogert, H. F., Cnossen, M. C., de Ruiter, G. C. W., Haitsma, I., Polinder, S., . . . CENTER-TBI, I. a. (2019). Correction to: Variation in neurosurgical management of traumatic brain injury. Acta Neurochirurgica, 161(3), 451-455
Open this publication in new window or tab >>Correction to: Variation in neurosurgical management of traumatic brain injury
Show others...
2019 (English)In: Acta Neurochirurgica, ISSN 0001-6268, E-ISSN 0942-0940, Vol. 161, no 3, p. 451-455Article in journal (Refereed) Published
Place, publisher, year, edition, pages
Springer, 2019
National Category
Clinical Medicine Neurology Surgery
Identifiers
urn:nbn:se:oru:diva-76159 (URN)10.1007/s00701-019-03815-6 (DOI)000460607500003 ()30715604 (PubMedID)2-s2.0-85061403050 (Scopus ID)
Note

Correction to Variation in neurosurgical management of traumatic brain injury: a survey in 68 centers participating in the CENTER-TBI study (2019) Acta Neurochirurgica, 161 (3), pp. 435-449. The collaborator names are inverted.

Available from: 2019-09-06 Created: 2019-09-06 Last updated: 2019-09-19Bibliographically approved
Hernández-Alvarez, M. I., Sebastián, D., Vives, S., Ivanova, S., Bartoccioni, P., Kakimoto, P., . . . Zorzano, A. (2019). Deficient Endoplasmic Reticulum-Mitochondrial Phosphatidylserine Transfer Causes Liver Disease. Cell, 177(4), 881-895.e17
Open this publication in new window or tab >>Deficient Endoplasmic Reticulum-Mitochondrial Phosphatidylserine Transfer Causes Liver Disease
Show others...
2019 (English)In: Cell, ISSN 0092-8674, E-ISSN 1097-4172, Vol. 177, no 4, p. 881-895.e17Article in journal (Refereed) Published
Abstract [en]

Non-alcoholic fatty liver is the most common liver disease worldwide. Here, we show that the mitochondrial protein mitofusin 2 (Mfn2) protects against liver disease. Reduced Mfn2 expression was detected in liver biopsies from patients with non-alcoholic steatohepatitis (NASH). Moreover, reduced Mfn2 levels were detected in mouse models of steatosis or NASH, and its re-expression in a NASH mouse model ameliorated the disease. Liver-specific ablation of Mfn2 in mice provoked inflammation, triglyceride accumulation, fibrosis, and liver cancer. We demonstrate that Mfn2 binds phosphatidylserine (PS) and can specifically extract PS into membrane domains, favoring PS transfer to mitochondria and mitochondrial phosphatidylethanolamine (PE) synthesis. Consequently, hepatic Mfn2 deficiency reduces PS transfer and phospholipid synthesis, leading to endoplasmic reticulum (ER) stress and the development of a NASH-like phenotype and liver cancer. Ablation of Mfn2 in liver reveals that disruption of ER-mitochondrial PS transfer is a new mechanism involved in the development of liver disease.

Place, publisher, year, edition, pages
Cell Press, 2019
Keywords
MAMs, Mfn2, NASH, mitochondria, phosphatidylserine, phospholipid transfer
National Category
Gastroenterology and Hepatology Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Identifiers
urn:nbn:se:oru:diva-74195 (URN)10.1016/j.cell.2019.04.010 (DOI)000466843000010 ()31051106 (PubMedID)2-s2.0-85064698279 (Scopus ID)
Note

Funding Agencies:

CONACYT, Mexico  

MICINN Spain  

Coordenacao de Aperfeicoamento do Pessoal de Nivel Superior (CAPES)  

MINECO  SAF201675246R 

Generalitat de Catalunya (ICREA Academia)  2014SGR48  2017SGR696 

INFLAMES (ISCIII) PIE-14/00045 

CIBERDEM, ISCIII, INTERREG IV-B-SUDOE-FEDER (DIOMED)  SOE1/P1/E178 

"la Caixa'' Foundation  

Miguel Servet tenure-track program from the Fondo de Investigacion Sanitaria  CP10/00438  CPII16/00008 

ERD  

MINECO through the Centres of Excellence Severo Ochoa Award  

CERCA Programme of the Generalitat de Catalunya 

Available from: 2019-05-13 Created: 2019-05-13 Last updated: 2019-06-19Bibliographically approved
Geng, D., Musse, A. A., Wigh, V., Carlsson, C., Engwall, M., Oresic, M., . . . Hyötyläinen, T. (2019). Effect of perfluorooctanesulfonic acid (PFOS) on the liver lipid metabolism of the developing chicken embryo. Ecotoxicology and Environmental Safety, 170, 691-698
Open this publication in new window or tab >>Effect of perfluorooctanesulfonic acid (PFOS) on the liver lipid metabolism of the developing chicken embryo
Show others...
2019 (English)In: Ecotoxicology and Environmental Safety, ISSN 0147-6513, E-ISSN 1090-2414, Vol. 170, p. 691-698Article in journal (Refereed) Published
Abstract [en]

Perfluorooctanesulfonate (PFOS) is a well-known contaminant in the environment and it has shown to disrupt multiple biological pathways, particularly those related with lipid metabolism. In this study, we have studied the impact of in ovo exposure to PFOS on lipid metabolism in livers in developing chicken embryos using lipidomics for detailed characterization of the liver lipidome. We used an avian model (Gallus gallus domesticus) for in ovo treatment at two levels of PFOS. The lipid profile of the liver of the embryo was investigated by ultra-high performance liquid chromatography combined with quadrupole-time-of-flight mass spectrometry and by gas chromatography mass spectrometry. Over 170 lipids were identified, covering phospholipids, ceramides, di- and triacylglycerols, cholesterol esters and fatty acid composition of the lipids. The PFOS exposure caused dose dependent changes in the lipid levels, which included upregulation of specific phospholipids associated with the phosphatidylethanolamine N-methyltransferase (PEMT) pathway, triacylglycerols with low carbon number and double bond count as well as of lipotoxic ceramides and diacylglycerols. Our data suggest that at lower levels of exposure, mitochondrial fatty acid β-oxidation is suppressed while the peroxisomal fatty acid β -oxidation is increased. At higher doses, however, both β -oxidation pathways are upregulated.

Place, publisher, year, edition, pages
Elsevier, 2019
Keywords
Avian model, Lipidomics, Liver metabolism, Mass spectrometry, Perfluorooctanesulfonate
National Category
Pharmaceutical Sciences
Identifiers
urn:nbn:se:oru:diva-71192 (URN)10.1016/j.ecoenv.2018.12.040 (DOI)000456890700083 ()30580163 (PubMedID)2-s2.0-85058940877 (Scopus ID)
Funder
Swedish Research Council, 2016-05176Swedish Research Council FormasKnowledge Foundation
Available from: 2019-01-08 Created: 2019-01-08 Last updated: 2019-03-04Bibliographically approved
Luukkonen, P. K., Nick, A., Hölttä-Vuori, M., Thiele, C., Isokuortti, E., Lallukka-Brück, S., . . . Yki-Järvinen, H. (2019). Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids. JCI Insight, 4(16), Article ID 127902.
Open this publication in new window or tab >>Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids
Show others...
2019 (English)In: JCI Insight, ISSN 2379-3708, Vol. 4, no 16, article id 127902Article in journal (Refereed) Published
Abstract [en]

The common patatin-like phospholipase domain-containing protein 3 (PNPLA3) variant I148M predisposes to nonalcoholic liver disease but not its metabolic sequelae. We compared the handling of labeled polyunsaturated fatty acids (PUFAs) and saturated fatty acids (SFA) in vivo in humans and in cells harboring different PNPLA3 genotypes. In 148M homozygous individuals, triglycerides (TGs) in very low-density lipoproteins (VLDL) were depleted of PUFAs both under fasting and postprandial conditions compared with 148I homozygotes, and the PUFA/SFA ratio in VLDL-TGs was lower relative to the chylomicron precursor pool. In human PNPLA3-148M and PNPLA3-KO cells, PUFA but not SFA incorporation into TGs was increased at the expense of phosphatidylcholines, and under lipolytic conditions, PUFA-containing diacylglycerols (DAGs) accumulated compared with PNPLA3-148I cells. Polyunsaturated TGs were increased, while phosphatidylcholines (PCs) were decreased in the human liver in 148M homozygous individuals as compared with 148I homozygotes. We conclude that human PNPLA3-I148M is a loss-of-function allele that remodels liver TGs in a polyunsaturated direction by impairing hydrolysis/transacylation of PUFAs from DAGs to feed phosphatidylcholine synthesis.

Place, publisher, year, edition, pages
American Society for Clinical Investigation (ASCI), 2019
Keywords
Genetic variation, Hepatitis, Hepatology, Metabolism
National Category
Physiology
Identifiers
urn:nbn:se:oru:diva-75893 (URN)10.1172/jci.insight.127902 (DOI)000482229000011 ()31434800 (PubMedID)
Note

Funding Agencies:

Academy of Finland  309263  282192  307415  312491 

EU H2020 project Elucidating Pathways of Steatohepatitis (HY EPoS grant)  634413 

H2020-JTI-IMI2 EU project  777377-2 

EVO foundation  

Paulo foundation  

Sigrid Juselius foundation  

Finnish Medical foundation  

Alfred Kordelin foundation  

Liv och Hälsa foundation 

Available from: 2019-08-26 Created: 2019-08-26 Last updated: 2019-09-10Bibliographically approved
Madrid-Gambin, F., Focking, M., Sabherwal, S., Heurich, M., English, J. A., O'Gorman, A., . . . Brennan, L. (2019). Integrated Lipidomics and Proteomics Point to Early Blood-Based Changes in Childhood Preceding Later Development of Psychotic Experiences: Evidence From the Avon Longitudinal Study of Parents and Children. Biological Psychiatry, 86(1), 25-34
Open this publication in new window or tab >>Integrated Lipidomics and Proteomics Point to Early Blood-Based Changes in Childhood Preceding Later Development of Psychotic Experiences: Evidence From the Avon Longitudinal Study of Parents and Children
Show others...
2019 (English)In: Biological Psychiatry, ISSN 0006-3223, E-ISSN 1873-2402, Vol. 86, no 1, p. 25-34Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: The identification of early biomarkers of psychotic experiences (PEs) is of interest because early diagnosis and treatment of those at risk of future disorder is associated with improved outcomes. The current study investigated early lipidomic and coagulation pathway protein signatures of later PEs in subjects from the Avon Longitudinal Study of Parents and Children cohort.

METHODS: Plasma of 115 children (12 years of age) who were first identified as experiencing PEs at 18 years of age (48 cases and 67 controls) were assessed through integrated and targeted lipidomics and semitargeted proteomics approaches. We assessed the lipids, lysophosphatidylcholines (n = 11) and phosphatidylcholines (n = 61), and the protein members of the coagulation pathway (n = 22) and integrated these data with complement pathway protein data already available on these subjects.

RESULTS: Twelve phosphatidylcholines, four lysophosphatidylcholines, and the coagulation protein plasminogen were altered between the control and PEs groups after correction for multiple comparisons. Lipidomic and proteomic datasets were integrated into a multivariate network displaying a strong relationship between most lipids that were significantly associated with PEs and plasminogen. Finally, an unsupervised clustering approach identified four different clusters, with one of the clusters presenting the highest case-control ratio (p < .01) and associated with a higher concentration of smaller low-density lipoprotein cholesterol particles.

CONCLUSIONS: Our findings indicate that the lipidome and proteome of subjects who report PEs at 18 years of age are already altered at 12 years of age, indicating that metabolic dysregulation may contribute to an early vulnerability to PEs and suggesting crosstalk between these lysophosphatidylcholines, phosphatidylcholines, and coagulation and complement proteins.

Place, publisher, year, edition, pages
Elsevier, 2019
Keywords
ALSPAC, Early life, Integration, Lipidomics, Proteomics, Psychotic episode
National Category
Neurology Psychiatry
Identifiers
urn:nbn:se:oru:diva-75212 (URN)10.1016/j.biopsych.2019.01.018 (DOI)000472860900007 ()30878195 (PubMedID)2-s2.0-85062721715 (Scopus ID)
Funder
Wellcome trust, 102215/2/13/2
Note

Funding Agencies:Health Research Board  HRA-POR-2013-282  HRBCSA2012/8 

European Research Council  647783  724809 

European Union FP7 collaborative project METSY  602478 

National Institute for Health Research Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol  

Irish Health Research Board Clinician Scientist Award  

UK Medical Research Council  102215/2/13/2 

Available from: 2019-07-26 Created: 2019-07-26 Last updated: 2019-07-26Bibliographically approved
Fang, W., Santosh, L., Oresic, M. & Hyötyläinen, T. (2019). Lipidomes in health and disease: Analytical strategies and considerations. TrAC. Trends in analytical chemistry, 120, Article ID 115664.
Open this publication in new window or tab >>Lipidomes in health and disease: Analytical strategies and considerations
2019 (English)In: TrAC. Trends in analytical chemistry, ISSN 0165-9936, E-ISSN 1879-3142, Vol. 120, article id 115664Article, review/survey (Refereed) Published
Abstract [en]

Lipidomics is a rapidly-growing field which focuses on global characterization of lipids at molecular and systems levels. As small changes in the concentrations of lipids may have important physiological consequences, much attention in the field has recently been paid to more accurate quantitation and identification of lipids. Community-wide efforts have been initiated, aiming to develop best practices for lipidomic analyses and reporting of lipidomic data. Nevertheless, current approaches for comprehensive analysis of lipidomes have some inherent challenges and limitations. Additionally, there is, currently, limited knowledge concerning the impacts of various external and internal exposures on lipid levels. In this review, we discuss the recent progress in lipidomics analysis, with a primary focus on analytical approaches, as well as on the different sources of variation in quantifying lipid levels, both technical and biological.

Place, publisher, year, edition, pages
Elsevier, 2019
Keywords
Biomarkers, Lipid identification, Lipidomics, Mass spectrometry, Metabolomics, Quantification
National Category
Bioinformatics and Systems Biology Biochemistry and Molecular Biology
Identifiers
urn:nbn:se:oru:diva-77194 (URN)10.1016/j.trac.2019.115664 (DOI)2-s2.0-85072601123 (Scopus ID)
Available from: 2019-10-11 Created: 2019-10-11 Last updated: 2019-10-11Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0002-2856-9165

Search in DiVA

Show all publications